VivoSeq
Other

Dentinal Hypersensitivity

0

Pipeline Programs

3

Active Trials

1

Companies Involved

Dentinal Hypersensitivity is an early-stage landscape with 0 programs across 1 company. The most active players are GSK.

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

30

clinical trials

Completed26 · 87%
Not yet recruiting2 · 7%
Recruiting1 · 3%
Unknown status1 · 3%

Trial Activity

30 trials

Comparison of LASER Therapy and Desensitizing Agents in Dentinal Hypersensitivity
Not yet recruiting··N/A·NCT06759454·172 enrolled
Efficacy of Herbal Dentifrice for Management of Dentinal Hypersensitivity
Completed··Phase 3·NCT05852366·75 enrolled
Dentinal Hypersensitivity Reduction
Completed··Phase 3·NCT06244290·123 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)